Table 3 Association of MCT expression with the clinical-pathological parameters

Age

0.153

0.076

0.403

 >51

48

32 (66.7)

12 (25.0)

29 (60.4)

 ≤51

37

19 (51.4)

16 (43.2)

19 (51.4)

Gender

0.716

0.174

0.463

 Female

33

19 (57.6)

8 (24.2)

17 (51.5)

 Male

52

32 (61.5)

20 (38.5)

31 (59.6)

Race

0.686

0.896

0.832

 Caucasian

63

37 (58.7)

21 (33.3)

36 (57.1)

 Not Caucasian

22

14 (63.6)

7 (31.8)

12 (54.5)

Local

0.586

0.439

0.154

 Lower extremities

63

37 (58.7)

22 (34.9)

33 (52.4)

 Upper extremities

23

15 (65.2)

6 (26.1)

16 (69.6)

Cell lineage

0.066

<0.001

<0.001

 Fibroblastic/myofibroblastic

28

16 (57.1)

9 (32.1)

16 (57.1)

 Smooth muscle

17

12 (70.6)

3 (17.6)

13 (76.5)

 Lipogenic

17

6 (35.3)

13 (76.5)

2 (11.8)

 Peripheral nerve

7

4 (57.1)

2 (28.6)

4 (57.1)

 Miscellaneous

17

14 (82.4)

1 (5.9)

14 (82.4)

Cellular pleomorphism

0.034

0.010

0.009

 Absence of pleomorphic cells

54

28 (51.9)

23 (42.6)

25 (46.3)

 Presence of pleomorphic cells

32

24 (75.0)

5 (15.6)

24 (75.0)

Grade

<0.001

<0.001

0.011

 Low grade (I)

19

4 (21.1)

14 (73.7)

6 (31.6)

 High grade (II e III)

67

48 (71.6)

14 (20.9)

43 (64.2)

Disease progression

0.018

0.865

0.060

 No

25

10 (40.0)

8 (32.0)

10 (40.0)

 Yes

56

39 (67.2)

20 (33.9)

35 (62.5)

 Disease recurrence

0.847

0.640

0.204

 Absent

48

29 (60.4)

15 (31.2)

24 (50.0)

 Present

36

21 (58.3)

13 (36.1)

23 (63.9)

Metastasis

0.156

0.122

0.249

 Absent

44

23 (52.3)

18 (40.9)

22 (50.0)

 Present

40

27 (67.5)

10 (25.0)

25 (62.5)